Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
应用:
(αR,βS)-rel-Bedaquiline is a promising diarylquinoline candidate in clinical development for the treatment of tuberculosis. (αR,βS)-rel-Bedaquiline inhibits mycobacterial ATP synthase and displays high activity against both drug-susceptible and multidrug-resistant strains of Mycobacterium tuberculosis.
您的位置：
